Literature DB >> 3804497

Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents.

U Regenass, M Müller, E Curschellas, A Matter.   

Abstract

The anti-tumor activity of partially purified tumor necrosis factor (TNF) was analysed in combination with chemotherapeutic drugs against intradermally transplanted Meth A sarcoma. Tumors were allowed to grow until they reached an average diameter of about 8 mm. TNF was given once i.v. (16,000 units as determined on L-M cells) and the chemotherapeutic agents adriamycin (1-10 mg/kg), 5-FU (3-100 mg/kg), cyclophosphamide (50-200 mg/kg) were applied once i.p. 4 hr after TNF injection. The strongest anti-tumor effects in normal BALB/c mice were observed when TNF was combined with the following doses of chemotherapeutic agents: cyclophosphamide 100 mg/kg, adriamycin 5 mg/kg, 5-FU 30-100 mg/kg. The most effective combinations induced complete regressions. When TNF was combined with varying doses of adriamycin and cyclophosphamide, bell-shaped dose-response curves were obtained. Experiments were repeated in Meth A sarcoma-bearing BALB/c nu/nu mice. In this case TNF combinations with cyclophosphamide and 5-FU did not induce tumor regressions. The highest dose of the chemotherapeutic agent was the most effective in drug combinations. Histological analysis revealed a potentiation of the TNF-induced necrosis by cyclophosphamide. Increased hyperemia and extravasation of erythrocytes could be found in tumors of animals treated with the drug combination.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3804497     DOI: 10.1002/ijc.2910390224

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Synergistic cytotoxicity of human recombinant tumour necrosis factor alpha combined with microtubule effectors.

Authors:  J Baumgart; B Schlott; J Suehnel; W Vater; W Schulze; D Behnke
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.

Authors:  Dennis Kobelt; Jutta Aumann; Manuel Schmidt; Burghardt Wittig; Iduna Fichtner; Diana Behrens; Margit Lemm; Greta Freundt; Peter M Schlag; Wolfgang Walther
Journal:  Mol Oncol       Date:  2014-01-18       Impact factor: 6.603

3.  In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.

Authors:  D Liénard; F J Lejeune; P Ewalenko
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

4.  Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.

Authors:  H Eda; K Fujimoto; S Watanabe; M Ura; A Hino; Y Tanaka; K Wada; H Ishitsuka
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.

Authors:  A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1991

6.  In vitro antiproliferative efficacy of interferon-alpha, -gamma and tumor necrosis factor on two human renal tumor xenografts.

Authors:  A J Beniers; W P Peelen; B T Hendriks; J A Schalken; J C Romijn; F M Debruyne
Journal:  Urol Res       Date:  1988

7.  Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice.

Authors:  C M Krawczyk; S Verstovsek; P Ujházy; D Maccubbin; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

8.  Cytokine-mediated reversal of multidrug resistance.

Authors:  U Stein; W Walther
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

9.  Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.

Authors:  A L Jones; J L Millar; B C Millar; B Powell; P Selby; A Winkley; S Lakhani; M E Gore; T J McElwain
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

10.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.

Authors:  P T Nooijen; E R Manusama; A M Eggermont; L Schalkwijk; J Stavast; R L Marquet; R M de Waal; D J Ruiter
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.